Immediate Implant Placement Using the Socket Shield Technique in Maxillary Esthetic Zone

Hams Hamed Abdelrahman

Status

Not yet enrolling

Conditions

Maxillary Esthetic Zone

Socket Shield Technique

Treatments

Procedure: Socket shield concept and immediate implant placement

Study type

Interventional

Funder types

Other

Identifiers

NCT07082634

2025-H-0176-D-M-0796

Details and patient eligibility

About

Immediate implant placement in the esthetic zone is an approach that helps preserve soft and hard tissue architecture. However, post extraction bone resorption is still a significant challenge. The socket shield technique (SST) has emerged as a promising way for preserving the buccal plate, potentially improving implant stability and reducing radiographic bone loss. The aim of the present study is to evaluate the clinical and radiographic outcomes of the socket shield technique in the maxillary esthetic zone by assessing implant stability, radiographic bone loss as well as esthetic outcome over a specified follow-up period.

Enrollment

8 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a non-restorable maxillary tooth in the aesthetic zone indicated for extraction and subsequent immediate implant placement.
Patients with extraction socket Type I.
A good standard of oral hygiene.

Exclusion criteria

Patients with extraction socket Type II or III, with defect in the buccal plate.
Absence of at least 2 mm bone apical to the extraction socket, necessary to obtain adequate primary stability for the implant assessed by pre-operative radiographic evaluation.
The presence of any local factor that may interfere with extraction as tooth ankylosis.
Patients with deciduous teeth.
Patients with bruxism
Heavy smokers.
Systemic conditions that are considered as a contraindication for placement of implant or those that may interfere with wound healing and immunocompromised conditions and uncontrolled autoimmune diseases.
History of oral or intravenous bisphosphonate therapy or any treatments with other medications that may interfere with bone metabolism within the past 12 months.
Patients receiving radiotherapy or chemotheraphy.
Patient with active infection or chronic infection with severe bone loss.